Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vectura Breathes Easy As It Enters Eventful 2019

Executive Summary

With a steady stream of royalties coming in from Flutiform and Ultibro and a decent pipeline of innovative respiratory drugs and generics, Vectura has presented a promising update for the year ahead.

You may also be interested in...



Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio

Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.

Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard

FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.

Novo Nordisk Braced For China Insulin Scheme Impact

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel